GOOGLE’S AI DRUG DISCOVERY SPINOUT RAISES $2.1 BILLION TO SCALE THE ENGINE THAT COULD REPLACE PHARMACEUTICAL LABS Isomorphic Labs, the drug discovery company spun out of Google DeepMind, has secured $2.1 billion in funding to scale its AI-powered drug design platform. The company builds on the AlphaFold protein structure prediction breakthrough and applies it to the full pipeline of drug discovery, from identifying viable molecular targets to designing candidate compounds that can reach clinical trials. The significance of this number is not just the size of the raise. It reflects a growing conviction among major investors that AI drug discovery is not a research curiosity but a replacement for the traditional pharmaceutical R&D model. Pfizer has already used similar AI systems to scan millions of compounds and identify viable drug candidates in 30 days, a process that previously took years. Eli Lilly opened a dedicated pharmaceutical AI supercomputer this year built on NVIDIA hardware specifically for this work. The standard drug development timeline runs 10 to 15 years from molecule to market. AI systems are beginning to compress that to 3 to 5 years on the discovery and preclinical side. The capital flowing into companies like Isomorphic Labs represents a bet that the next generation of cancer treatments, antivirals, and neurological drugs will be designed by machines, not by chemists at benches. That shift, if it holds, touches every human life on the planet. Keywords: Isomorphic Labs funding, AI drug discovery, Google DeepMind biotech, AI pharmaceutical research